Loading…

Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors

[Display omitted] •New pyrazolopyrimidines were designed to target hA1 and hA2A adenosine receptors.•Different groups were evaluated at the 2- and 5-positions of the scaffold.•The 2-(2-methoxybenzyl) moiety afforded the highest hA2A AR affinities.•The 5-(5-methylfuran-2-yl) group achieved the best h...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2016-06, Vol.24 (12), p.2794-2808
Main Authors: Squarcialupi, Lucia, Falsini, Matteo, Catarzi, Daniela, Varano, Flavia, Betti, Marco, Varani, Katia, Vincenzi, Fabrizio, Dal Ben, Diego, Lambertucci, Catia, Volpini, Rosaria, Colotta, Vittoria
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3118-72abfee72666952150a7b651488b61a0c7dce37b541cf93e9f376a9f15735cb23
cites cdi_FETCH-LOGICAL-c3118-72abfee72666952150a7b651488b61a0c7dce37b541cf93e9f376a9f15735cb23
container_end_page 2808
container_issue 12
container_start_page 2794
container_title Bioorganic & medicinal chemistry
container_volume 24
creator Squarcialupi, Lucia
Falsini, Matteo
Catarzi, Daniela
Varano, Flavia
Betti, Marco
Varani, Katia
Vincenzi, Fabrizio
Dal Ben, Diego
Lambertucci, Catia
Volpini, Rosaria
Colotta, Vittoria
description [Display omitted] •New pyrazolopyrimidines were designed to target hA1 and hA2A adenosine receptors.•Different groups were evaluated at the 2- and 5-positions of the scaffold.•The 2-(2-methoxybenzyl) moiety afforded the highest hA2A AR affinities.•The 5-(5-methylfuran-2-yl) group achieved the best hA2A affinities.•The hA2A and hA1 affinities were rationalized by molecular docking investigations. A new series of 7-aminopyrazolo[4,3-d]pyrimidine derivatives (1–31) were synthesized to evaluate some structural modifications at the 2- and 5-positions aimed at shifting affinity towards the human (h) A2A adenosine receptor (AR) or both hA2A and hA1 ARs. The most active compounds were those featured by a 2-furyl or 5-methylfuran-2-yl moiety at position 5, combined with a benzyl or a substituted-benzyl group at position 2. Several of these derivatives (22–31) displayed nanomolar affinity for the hA2A AR (Ki=3.62–57nM) and slightly lower for the hA1 ARs, thus showing different degrees (3–22 fold) of hA2A versus hA1 selectivity. In particular, the 2-(2-methoxybenzyl)-5-(5-methylfuran-2-yl) derivative 25 possessed the highest hA2A and hA1 AR affinities (Ki=3.62nM and 18nM, respectively) and behaved as potent antagonist at both these receptors (cAMP assays). Its 2-(2-hydroxybenzyl) analog 26 also showed a high affinity for the hA2A AR (Ki=5.26nM) and was 22-fold selective versus the hA1 subtype. Molecular docking investigations performed at the hA2A AR crystal structure and at a homology model of the hA1 AR allowed us to represent the hypothetical binding mode of our derivatives and to rationalize the observed SARs.
doi_str_mv 10.1016/j.bmc.2016.04.048
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1793214303</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089616302917</els_id><sourcerecordid>1793214303</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3118-72abfee72666952150a7b651488b61a0c7dce37b541cf93e9f376a9f15735cb23</originalsourceid><addsrcrecordid>eNp9kEFrFTEQx4Mo9rX6AbxIjh7MM5PsJlk8PUqtQsGLnkRCNjvb5rGbrMm-Yj350U37qkdhYCbkPz-YHyGvgG-Bg3q33_az34o6bnlTyzwhG2hUw6Ts4CnZ8E4Zxk2nTshpKXvOuWg6eE5OhAYFRpsN-X3xc5lSDvGarjdIBaMuDrRlSyphDSkWmsaHn-Uuu19pSt-at5IN3-szzGEIkWnm5hATLd6NY5oGuia6unyNK705zC7SHTwwd2JH3YCxgiPSjB6XNeXygjwb3VTw5WM_I18_XHw5_8iuPl9-Ot9dMS8BDNPC9SOiFkqprhXQcqd71UJjTK_Aca8Hj1L3bQN-7CR2o9TKdSO0Wra-F_KMvDlyl5x-HLCsdg7F4zS5iOlQLOhOCmgklzUKx6jPqZSMo13qsS7fWeD2Xrzd2yre3ou3vKll6s7rR_yhn3H4t_HXdA28PwawHnkbMNviA0aPQ6guVjuk8B_8H4ywkm0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1793214303</pqid></control><display><type>article</type><title>Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors</title><source>Elsevier</source><creator>Squarcialupi, Lucia ; Falsini, Matteo ; Catarzi, Daniela ; Varano, Flavia ; Betti, Marco ; Varani, Katia ; Vincenzi, Fabrizio ; Dal Ben, Diego ; Lambertucci, Catia ; Volpini, Rosaria ; Colotta, Vittoria</creator><creatorcontrib>Squarcialupi, Lucia ; Falsini, Matteo ; Catarzi, Daniela ; Varano, Flavia ; Betti, Marco ; Varani, Katia ; Vincenzi, Fabrizio ; Dal Ben, Diego ; Lambertucci, Catia ; Volpini, Rosaria ; Colotta, Vittoria</creatorcontrib><description>[Display omitted] •New pyrazolopyrimidines were designed to target hA1 and hA2A adenosine receptors.•Different groups were evaluated at the 2- and 5-positions of the scaffold.•The 2-(2-methoxybenzyl) moiety afforded the highest hA2A AR affinities.•The 5-(5-methylfuran-2-yl) group achieved the best hA2A affinities.•The hA2A and hA1 affinities were rationalized by molecular docking investigations. A new series of 7-aminopyrazolo[4,3-d]pyrimidine derivatives (1–31) were synthesized to evaluate some structural modifications at the 2- and 5-positions aimed at shifting affinity towards the human (h) A2A adenosine receptor (AR) or both hA2A and hA1 ARs. The most active compounds were those featured by a 2-furyl or 5-methylfuran-2-yl moiety at position 5, combined with a benzyl or a substituted-benzyl group at position 2. Several of these derivatives (22–31) displayed nanomolar affinity for the hA2A AR (Ki=3.62–57nM) and slightly lower for the hA1 ARs, thus showing different degrees (3–22 fold) of hA2A versus hA1 selectivity. In particular, the 2-(2-methoxybenzyl)-5-(5-methylfuran-2-yl) derivative 25 possessed the highest hA2A and hA1 AR affinities (Ki=3.62nM and 18nM, respectively) and behaved as potent antagonist at both these receptors (cAMP assays). Its 2-(2-hydroxybenzyl) analog 26 also showed a high affinity for the hA2A AR (Ki=5.26nM) and was 22-fold selective versus the hA1 subtype. Molecular docking investigations performed at the hA2A AR crystal structure and at a homology model of the hA1 AR allowed us to represent the hypothetical binding mode of our derivatives and to rationalize the observed SARs.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/j.bmc.2016.04.048</identifier><identifier>PMID: 27161878</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>A1 and A2A adenosine receptor antagonists ; Amination ; G protein-coupled receptors ; Humans ; Ligand–adenosine receptor modeling studies ; Molecular Docking Simulation ; Purinergic P1 Receptor Antagonists - chemistry ; Purinergic P1 Receptor Antagonists - pharmacology ; Pyrazoles - chemistry ; Pyrazoles - pharmacology ; Pyrazolo[4,3-d]pyrimidines ; Pyrimidines - chemistry ; Pyrimidines - pharmacology ; Receptor, Adenosine A1 - metabolism ; Receptor, Adenosine A2A - metabolism</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2016-06, Vol.24 (12), p.2794-2808</ispartof><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3118-72abfee72666952150a7b651488b61a0c7dce37b541cf93e9f376a9f15735cb23</citedby><cites>FETCH-LOGICAL-c3118-72abfee72666952150a7b651488b61a0c7dce37b541cf93e9f376a9f15735cb23</cites><orcidid>0000-0002-6616-6885 ; 0000-0002-9296-6819</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27161878$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Squarcialupi, Lucia</creatorcontrib><creatorcontrib>Falsini, Matteo</creatorcontrib><creatorcontrib>Catarzi, Daniela</creatorcontrib><creatorcontrib>Varano, Flavia</creatorcontrib><creatorcontrib>Betti, Marco</creatorcontrib><creatorcontrib>Varani, Katia</creatorcontrib><creatorcontrib>Vincenzi, Fabrizio</creatorcontrib><creatorcontrib>Dal Ben, Diego</creatorcontrib><creatorcontrib>Lambertucci, Catia</creatorcontrib><creatorcontrib>Volpini, Rosaria</creatorcontrib><creatorcontrib>Colotta, Vittoria</creatorcontrib><title>Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>[Display omitted] •New pyrazolopyrimidines were designed to target hA1 and hA2A adenosine receptors.•Different groups were evaluated at the 2- and 5-positions of the scaffold.•The 2-(2-methoxybenzyl) moiety afforded the highest hA2A AR affinities.•The 5-(5-methylfuran-2-yl) group achieved the best hA2A affinities.•The hA2A and hA1 affinities were rationalized by molecular docking investigations. A new series of 7-aminopyrazolo[4,3-d]pyrimidine derivatives (1–31) were synthesized to evaluate some structural modifications at the 2- and 5-positions aimed at shifting affinity towards the human (h) A2A adenosine receptor (AR) or both hA2A and hA1 ARs. The most active compounds were those featured by a 2-furyl or 5-methylfuran-2-yl moiety at position 5, combined with a benzyl or a substituted-benzyl group at position 2. Several of these derivatives (22–31) displayed nanomolar affinity for the hA2A AR (Ki=3.62–57nM) and slightly lower for the hA1 ARs, thus showing different degrees (3–22 fold) of hA2A versus hA1 selectivity. In particular, the 2-(2-methoxybenzyl)-5-(5-methylfuran-2-yl) derivative 25 possessed the highest hA2A and hA1 AR affinities (Ki=3.62nM and 18nM, respectively) and behaved as potent antagonist at both these receptors (cAMP assays). Its 2-(2-hydroxybenzyl) analog 26 also showed a high affinity for the hA2A AR (Ki=5.26nM) and was 22-fold selective versus the hA1 subtype. Molecular docking investigations performed at the hA2A AR crystal structure and at a homology model of the hA1 AR allowed us to represent the hypothetical binding mode of our derivatives and to rationalize the observed SARs.</description><subject>A1 and A2A adenosine receptor antagonists</subject><subject>Amination</subject><subject>G protein-coupled receptors</subject><subject>Humans</subject><subject>Ligand–adenosine receptor modeling studies</subject><subject>Molecular Docking Simulation</subject><subject>Purinergic P1 Receptor Antagonists - chemistry</subject><subject>Purinergic P1 Receptor Antagonists - pharmacology</subject><subject>Pyrazoles - chemistry</subject><subject>Pyrazoles - pharmacology</subject><subject>Pyrazolo[4,3-d]pyrimidines</subject><subject>Pyrimidines - chemistry</subject><subject>Pyrimidines - pharmacology</subject><subject>Receptor, Adenosine A1 - metabolism</subject><subject>Receptor, Adenosine A2A - metabolism</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kEFrFTEQx4Mo9rX6AbxIjh7MM5PsJlk8PUqtQsGLnkRCNjvb5rGbrMm-Yj350U37qkdhYCbkPz-YHyGvgG-Bg3q33_az34o6bnlTyzwhG2hUw6Ts4CnZ8E4Zxk2nTshpKXvOuWg6eE5OhAYFRpsN-X3xc5lSDvGarjdIBaMuDrRlSyphDSkWmsaHn-Uuu19pSt-at5IN3-szzGEIkWnm5hATLd6NY5oGuia6unyNK705zC7SHTwwd2JH3YCxgiPSjB6XNeXygjwb3VTw5WM_I18_XHw5_8iuPl9-Ot9dMS8BDNPC9SOiFkqprhXQcqd71UJjTK_Aca8Hj1L3bQN-7CR2o9TKdSO0Wra-F_KMvDlyl5x-HLCsdg7F4zS5iOlQLOhOCmgklzUKx6jPqZSMo13qsS7fWeD2Xrzd2yre3ou3vKll6s7rR_yhn3H4t_HXdA28PwawHnkbMNviA0aPQ6guVjuk8B_8H4ywkm0</recordid><startdate>20160615</startdate><enddate>20160615</enddate><creator>Squarcialupi, Lucia</creator><creator>Falsini, Matteo</creator><creator>Catarzi, Daniela</creator><creator>Varano, Flavia</creator><creator>Betti, Marco</creator><creator>Varani, Katia</creator><creator>Vincenzi, Fabrizio</creator><creator>Dal Ben, Diego</creator><creator>Lambertucci, Catia</creator><creator>Volpini, Rosaria</creator><creator>Colotta, Vittoria</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6616-6885</orcidid><orcidid>https://orcid.org/0000-0002-9296-6819</orcidid></search><sort><creationdate>20160615</creationdate><title>Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors</title><author>Squarcialupi, Lucia ; Falsini, Matteo ; Catarzi, Daniela ; Varano, Flavia ; Betti, Marco ; Varani, Katia ; Vincenzi, Fabrizio ; Dal Ben, Diego ; Lambertucci, Catia ; Volpini, Rosaria ; Colotta, Vittoria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3118-72abfee72666952150a7b651488b61a0c7dce37b541cf93e9f376a9f15735cb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>A1 and A2A adenosine receptor antagonists</topic><topic>Amination</topic><topic>G protein-coupled receptors</topic><topic>Humans</topic><topic>Ligand–adenosine receptor modeling studies</topic><topic>Molecular Docking Simulation</topic><topic>Purinergic P1 Receptor Antagonists - chemistry</topic><topic>Purinergic P1 Receptor Antagonists - pharmacology</topic><topic>Pyrazoles - chemistry</topic><topic>Pyrazoles - pharmacology</topic><topic>Pyrazolo[4,3-d]pyrimidines</topic><topic>Pyrimidines - chemistry</topic><topic>Pyrimidines - pharmacology</topic><topic>Receptor, Adenosine A1 - metabolism</topic><topic>Receptor, Adenosine A2A - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Squarcialupi, Lucia</creatorcontrib><creatorcontrib>Falsini, Matteo</creatorcontrib><creatorcontrib>Catarzi, Daniela</creatorcontrib><creatorcontrib>Varano, Flavia</creatorcontrib><creatorcontrib>Betti, Marco</creatorcontrib><creatorcontrib>Varani, Katia</creatorcontrib><creatorcontrib>Vincenzi, Fabrizio</creatorcontrib><creatorcontrib>Dal Ben, Diego</creatorcontrib><creatorcontrib>Lambertucci, Catia</creatorcontrib><creatorcontrib>Volpini, Rosaria</creatorcontrib><creatorcontrib>Colotta, Vittoria</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Squarcialupi, Lucia</au><au>Falsini, Matteo</au><au>Catarzi, Daniela</au><au>Varano, Flavia</au><au>Betti, Marco</au><au>Varani, Katia</au><au>Vincenzi, Fabrizio</au><au>Dal Ben, Diego</au><au>Lambertucci, Catia</au><au>Volpini, Rosaria</au><au>Colotta, Vittoria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2016-06-15</date><risdate>2016</risdate><volume>24</volume><issue>12</issue><spage>2794</spage><epage>2808</epage><pages>2794-2808</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>[Display omitted] •New pyrazolopyrimidines were designed to target hA1 and hA2A adenosine receptors.•Different groups were evaluated at the 2- and 5-positions of the scaffold.•The 2-(2-methoxybenzyl) moiety afforded the highest hA2A AR affinities.•The 5-(5-methylfuran-2-yl) group achieved the best hA2A affinities.•The hA2A and hA1 affinities were rationalized by molecular docking investigations. A new series of 7-aminopyrazolo[4,3-d]pyrimidine derivatives (1–31) were synthesized to evaluate some structural modifications at the 2- and 5-positions aimed at shifting affinity towards the human (h) A2A adenosine receptor (AR) or both hA2A and hA1 ARs. The most active compounds were those featured by a 2-furyl or 5-methylfuran-2-yl moiety at position 5, combined with a benzyl or a substituted-benzyl group at position 2. Several of these derivatives (22–31) displayed nanomolar affinity for the hA2A AR (Ki=3.62–57nM) and slightly lower for the hA1 ARs, thus showing different degrees (3–22 fold) of hA2A versus hA1 selectivity. In particular, the 2-(2-methoxybenzyl)-5-(5-methylfuran-2-yl) derivative 25 possessed the highest hA2A and hA1 AR affinities (Ki=3.62nM and 18nM, respectively) and behaved as potent antagonist at both these receptors (cAMP assays). Its 2-(2-hydroxybenzyl) analog 26 also showed a high affinity for the hA2A AR (Ki=5.26nM) and was 22-fold selective versus the hA1 subtype. Molecular docking investigations performed at the hA2A AR crystal structure and at a homology model of the hA1 AR allowed us to represent the hypothetical binding mode of our derivatives and to rationalize the observed SARs.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27161878</pmid><doi>10.1016/j.bmc.2016.04.048</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-6616-6885</orcidid><orcidid>https://orcid.org/0000-0002-9296-6819</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2016-06, Vol.24 (12), p.2794-2808
issn 0968-0896
1464-3391
language eng
recordid cdi_proquest_miscellaneous_1793214303
source Elsevier
subjects A1 and A2A adenosine receptor antagonists
Amination
G protein-coupled receptors
Humans
Ligand–adenosine receptor modeling studies
Molecular Docking Simulation
Purinergic P1 Receptor Antagonists - chemistry
Purinergic P1 Receptor Antagonists - pharmacology
Pyrazoles - chemistry
Pyrazoles - pharmacology
Pyrazolo[4,3-d]pyrimidines
Pyrimidines - chemistry
Pyrimidines - pharmacology
Receptor, Adenosine A1 - metabolism
Receptor, Adenosine A2A - metabolism
title Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T17%3A45%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploring%20the%202-%20and%205-positions%20of%20the%20pyrazolo%5B4,3-d%5Dpyrimidin-7-amino%20scaffold%20to%20target%20human%20A1%20and%20A2A%20adenosine%20receptors&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Squarcialupi,%20Lucia&rft.date=2016-06-15&rft.volume=24&rft.issue=12&rft.spage=2794&rft.epage=2808&rft.pages=2794-2808&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/j.bmc.2016.04.048&rft_dat=%3Cproquest_cross%3E1793214303%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3118-72abfee72666952150a7b651488b61a0c7dce37b541cf93e9f376a9f15735cb23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1793214303&rft_id=info:pmid/27161878&rfr_iscdi=true